Belmont Capital’s Bristol-Myers Squibb BMY Stock Holding History

Belmont Capital’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-9,758	Closed	-$405K	–	176
2024 Q2	$405K	Hold	9,758	–	–	0.08%	85
2024 Q1	$529K	Hold	9,758	–	–	0.14%	55
2023 Q4	$501K	Buy	9,758 +3,108	+47%	+$163K	0.21%	46
2023 Q3	$386K	Buy	+6,650	New	+$407K	0.21%	44

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belmont Capital's BMY Position: Q3 2024 in Review

Belmont Capital sold out of Bristol-Myers Squibb (BMY) in Q3 2024, closing a stake of 9,758 shares — an estimated $405K sold.

Belmont Capital first reported a position in BMY in Q3 2023 and held it in 4 quarters. The position peaked at $529K in Q1 2024. 2,258 funds tracked by Wall St. Rank hold BMY as of Q3 2024.

Belmont Capital reported no remaining Bristol-Myers Squibb position as of Q3 2024 after selling out during the quarter.
Belmont Capital sold 9,758 Bristol-Myers Squibb shares in Q3 2024, an estimated $405K.
Belmont Capital first reported a position in Bristol-Myers Squibb in Q3 2023 and held it in 4 quarters.
Belmont Capital's Bristol-Myers Squibb position peaked at $529K in Q1 2024.
2,258 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2024.

Based on Belmont Capital's 13F filing for Q3 2024, filed 7 Nov 2024.